| Inflammation |
NCT05686759: A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. |
|
|
| Recruiting | 3b | 200 | RoW | Undiluted I.V.-Hepabig inj(GC5103), Diluted I.V.-Hepabig inj(GC5103) | GC Biopharma Corp | Hepatitis B | 12/24 | 09/25 | | |
NCT00986726: Effect of Temperature Controlled Laminar Airflow (TLA) on Rhinitis |
|
|
| Active, not recruiting | 3 | 14 | Europe | Protexo (Temperature controlled Laminar Airflow (TLA)), Protexo, Placebo TLA | Airsonett AB, Croel AB, Commitum AB | Asthma | 01/10 | 02/10 | | |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
2013-002190-22: Therapeutic clinical trial of three types of “Phlogosol concentrate for gargle” products, comparing their efficacy in reducing different inflammations of the oral cavity |
|
|
| Ongoing | 3 | 75 | Europe | Phlogosol Duo 30 mg/2 mg/ml koncentrátum toroköblítőhöz, Phlogosol külsőleges oldat, Phlogosol Uno 30 mg/ml koncentrátum toroköblítőhöz, Concentrate for gargle, Phlogosol külsőleges oldat | PannonPharma Ltd., PannonPharma Ltd. | Cold with sore throat, acute stomatitis, chronic pharyngitis acute tonsillitis, acute laryngitis, herpes stomatitis, superficial glossitis, acute and chronic gingivitis, ulcerative gingivitis, parodontitis, before or after tooth extraction, oral surgery, aphta recidivans, Inflammation of oral, throat, pharyngeal, mucosa etc., Diseases [C] - Mouth and tooth diseases [C07] | | | | |
NCT02256176 / 2014-003446-27: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection |
|
|
| Not yet recruiting | 3 | 40 | Europe | Simeprevir, TMC435, Sofosbuvir | Janssen R&D Ireland, Janssen R&D Ireland | Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C | 11/15 | 01/16 | | |
2005-004058-28: A phase III multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to that of Aventis Pasteur MSD’s hepatitis B vaccine, HBVAXPRO®, administered according to a 0, 1 months schedule, in pre-dialysis, peritoneal dialysis and haemodialysis patients (above or equal to 15 years of age), who did not respond to previous hepatitis B vaccination. |
|
|
| | 3 | 100 | Europe | Hepatitis B surface antigen, NA, HB-AS02V, NA, HBVAXPRO, HBVAXPRO | Henogen | Female and male pre-dialysis, peritoneal dialysis andhaemodialysis patients with documented evidence of nonresponseto previous hepatitis B vaccination [non-response toprevious hepatitis B vaccination defined as anti-HBs antibodyconcentrations <10 mIU/ml after at least one full course (witha minimum of four injections) of licensed vaccine asindicated for uraemic patients]. | | 10/07 | | |
2009-018112-26: Efficacy and tolerability of Citrus/Cydonia comp.® 1% solution for injection in patients with grass pollen seasonal allergic rhinitis: A randomised, double-blind, placebo-controlled clinical trial |
|
|
| Ongoing | 3 | 120 | Europe | Citrus/ Cydonia comp., Gencydo 1%, Gencydo 1% | Weleda AG | Grass pollen allergic rhinitis | | | | |
| Active, not recruiting | 3 | 197 | RoW | besifovir 150mg, tenofovir 300mg | IlDong Pharmaceutical Co Ltd | Chronic Hepatitis B | 02/16 | 01/23 | | |
2015-003147-19: To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS). Îα επιβεβαιωθεί η ασφάλεια και η αποτελεσματικότητα του NEUROASPIS PLP10® στη θεÏαπεία των ατόμων που Îχουν διαγνωστεί με υποτÏοπιάζουσα-διαλείπουσα πολλαπλή σκλήÏυνση (MS). |
|
|
| Ongoing | 3 | 220 | Europe | NEUROASPIS PLP10®, Oral liquid | PALUPA Medical Ltd, PALUPA Medical Ltd | Relapsing-Remitting Multiple Sclerosis (RRMS) ΥποτÏοπιάζουσα-Διαλείπουσα Πολλαπλή ΣκλήÏυνση, Multiple sclerosis (MS) is an inflammatory disease that destroys the myelin in the central nervous system causing neurological disorders and often severe disability. H σκλήÏυνση κατά πλάκας είναι μια φλεγμονώδης πάθηση που καταστÏÎφει την μυελίνη του κεντÏÎ¹ÎºÎ¿Ï Î½ÎµÏ…ÏÎ¹ÎºÎ¿Ï ÏƒÏ…ÏƒÏ„Î®Î¼Î±Ï„Î¿Ï‚ και Ï€Ïοκαλεί νευÏολογικÎÏ‚ διαταÏαχÎÏ‚ και, συχνά, σοβαÏή αναπηÏία., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT02821195: Study of Sanofi Pasteur's DTaP-IPV Hep B-PRP-T Combined Vaccine in Infants Who Previously Received Hepatitis B Vaccine |
|
|
| Recruiting | 3 | 354 | RoW | DTaP-IPV-Hep B-PRP-T combined vaccine, Hexaxim™ | National Institute of Hygiene and Epidemiology, Vietnam, Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b Infection | 12/16 | 03/17 | | |
NCT02836249: Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China) |
|
|
| Completed | 3 | 181 | RoW | TAF, GS-7340, Vemlidy®, TDF, Viread®, TAF Placebo, TDF Placebo | Gilead Sciences | HBV, Chronic HBV Infections | 12/16 | 07/23 | | |
NCT02836236: Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China) |
|
|
| Completed | 3 | 155 | RoW | TAF, GS-7340, Vemlidy®, TDF, Viread®, TAF Placebo, TDF Placebo | Gilead Sciences | HBV, Chronic HBV Infections | 02/17 | 09/23 | | |
2014-002659-25: An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085 |
|
|
| Not yet recruiting | 3 | 10 | Europe | Reslizumab, CEP-38072, Concentrate for solution for infusion | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Treatment for patients with eosinophilic asthma, A particular form of asthma characterized by the presence of a high number in the lungs of a certain type of white blood cells, called eosinophils, which lead to airways inflammation and symptoms., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2016-001921-15: Novel budesonide suppository vs. budesonide foam in acute ulcerative proctitis. |
|
|
| Ongoing | 3 | 576 | Europe | Budenofalk® suppositories (BUS), Budenofalk® 2 mg foam, Suppository, Rectal foam, Budenofalk® 2 mg foam | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Acute Ulcerative Proctitis, Acute Ulcerative Proctitis - Inflammation of the Rectum, Diseases [C] - Digestive System Diseases [C06] | | | | |
2016-002958-21: Study HCV-art: An Open-Label, pilot Study, to Explore the Clinical Safety and Efficacy of Sofosbuvir/Ledipasvir in Hepatitis C Virus (HCV) Chronic Patients with Arthritis Studio pilota, monocentrico, in aperto, per valutare sicurezza ed efficacia della combinazione sofosbuvir/ledipasvir in pazienti con epatite C cronica, genotipo 1, affetti da artrite cronica |
|
|
| Not yet recruiting | 3 | 50 | Europe | HARVONI, RIBAVIRINA, J05AX65, RIBAVIRINA, Film-coated tablet, Capsule, hard, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER | AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, Gilead | Chronic HCV associated with chronic arthritis. HCV cronica associata ad artrite cronica., Chronic HCV associated with chronic arthritis. HCV cronica associata ad artrite cronica., Diseases [C] - Virus Diseases [C02] | | | | |
2017-001728-23: Efficacy of golimumab in early axial spondyloarthritis (axSpA) in relation to gut inflammation, an early remission induction study (GO GUT). |
|
|
| Ongoing | 3 | 147 | Europe | Solution for injection in pre-filled pen, Simponi | Ghent University, Merck Sharp & Dohme, Vlaams Instituut voor Biotechnologie | early axial spondyloarthritis (axSpA) in relation to gut inflammation, early axial spondyloarthritis (axSpA) in relation to gut inflammation, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT01651403 / 2012-000586-20: Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection |
|
|
| Active, not recruiting | 3 | 90 | Europe, US, RoW | Tenofovir DF, Viread®, TDF Placebo | Gilead Sciences | Chronic Hepatitis B | 08/17 | 07/27 | | |
2017-001463-21: MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participants |
|
|
| Ongoing | 3 | 426 | Europe | MK-3682B, MK-3682B, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | Treatment of hepatitis C virus (HCV) infection, Treatment of chronic hepatitis C virus (HCV) infection, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003367-19: A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing cholangitis |
|
|
| Ongoing | 3 | 300 | Europe, RoW | Norursodeoxycholic acid, [NorUDCA], Capsule | Dr. Falk Pharma GmbH, DR. FALK PHARMA GMBH, Dr. Falk Pharma GmbH, | Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and fibro-obliterative destruction of extra-, and intrahepatic bile ducts. The disease is characterized by diffuse inflammation, fibrosis, and strictures of the intra- and/or extrahepatic bile ducts with an impaired biliary secretion of potentially aggressive bile fluid often leading to cirrhosis., Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic liver disease characterized by changes in the gall ducts inside and/or outside the liver, such as narrowing or enlargement., Diseases [C] - Digestive System Diseases [C06] | | | | |
2015-005389-51: Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE |
|
|
| Ongoing | 3 | 100 | Europe | RoActemra, Concentrate and solvent for solution for infusion, Tocilizumab | CHRU DE BREST, Laboratoire CHUGAI | Polymyalgia rHeumatica, Inflammatory disease in the elderly, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-003710-58: 8 weeks of Elbasvir/Grazoprevir in patients with Hepatitis C Elbasvir/Grazoprevir per 8 settimane nei pazienti con epatite C |
|
|
| Not yet recruiting | 3 | 75 | Europe | Zepatier, Tablet, ZEPATIER - 50 MG/100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (ALL/ALL)- 28 COMPRESSE | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Merck Sharp & Dohme | chronic hepatitis C epatite cronica da HCV, chronic hepatitis C epatite cronica da HCV, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-000246-19: A study of ART-123 in patients with coagulopathy due to sepsis and a concurrent diagnosis of shock and/or respiratory dysfunction that requires mechanical ventilation to treat hypoxemia. |
|
|
| Ongoing | 3 | 800 | Europe | ART-123, ART-123, Lyophilisate and solvent for solution for injection | Asahi Kasei Pharma America Corporation, Asahi Kasei Pharma America Corporation | Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome. In severe disease, the coagulation system becomes diffusely activated, with consumption of multiple clotting factors resulting in Disseminated Intravascular Coagulation (DIC)., Sepsis has been defined as infection complicated by a systemic inflammatory response syndrome.Coagulopathy is associated with increased mortality in sepsis, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2017-000694-37: A study to evaluate how effective and safe a simplified treatment monitoring strategy is when applied to people with chronic hepatitis C virus infection without liver disease and taking glecaprevir/pibrentasvir for 8 weeks |
|
|
| Not yet recruiting | 3 | 375 | Europe | glecaprevir/pibrentasvir, ABT-493/ABT-530, Film-coated tablet | University of New South Wales Sydney, Abbvie Pty Ltd, University of New South Wales Sydney | Chronic hepatitis C virus infection, Chronic hepatitis C infection is infection with hepatitis C virus for more than 6 months, Diseases [C] - Virus Diseases [C02] | | | | |
2018-001931-27: Comparison of therapeutic strategies in childhood ARthritiS Confronto di strategie terapeutiche nell'artrite idiopatica giovanile |
|
|
| Not yet recruiting | 3 | 260 | Europe | Solution for infusion in pre-filled syringe, Powder and solution for solution for injection, Reumaflex, Enbrel | IRCCS Istituto Giannina Gaslini, AIFA, Compagnia di San Paolo, Pfizer | Juvenile idiopathic arthritis (JIA) is an umbrella term that encompasses a heterogeneous group of disorders characterised by prolonged synovial inflammation that may cause destructive damage to joint structures. Permanent changes may also develop in extraarticular organs, particularly the eye (as a complication of chronic anterior uveitis), or may result from side effects of medications. L’artrite idiopatica giovanile (AIG) è una malattia cronica caratterizzata da infiammazione persistente alle articolazioni; i segni tipici di infiammazione alle articolazioni sono dolore, gonfiore e limitazione dei movimenti. "Idiopatica" significa che non conosciamo la causa della malattia e "giovanile", in questo caso, significa che l’inizio dei sintomi di solito avviene prima dei 16 anni d’età., Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent inflammation of the joints, pain, swelling and limitation of motion. L’artrite idiopatica giovanile (AIG) è una malattia cronica caratterizzata da infiammazione persistente alle articolazioni, dolore, gonfiore e limitazione dei movimenti., Diseases [C] - Immune System Diseases [C20] | | | | |
2017-001071-23: A trial to investigate the immunogenicity and safety of the Dengue vaccine (TDV) when it is injected together with Hepatitis A vaccine in healthy adult subjects |
|
|
| Not yet recruiting | 3 | 900 | Europe | Tetravalent Dengue Vaccine Candidate (TDV), Hepatitis A Vaccine (inactivated, adsorbed), TAK-003, Powder and solution for solution for injection, Suspension for injection, HAVRIX | Takeda Vaccines, Inc., Takeda Vaccines, Inc. | Healthy Volunteers"Vaccination against Dengue Fever and co-administration with Hepatitis A vaccine", Dengue fever is caused by infection with dengue virus, a RNA virus that occurs as 4 recognized serotypes: DENV-1, -2, -3, or -4. These viruses are transmitted fromhuman to human by mosquitoes., Diseases [C] - Virus Diseases [C02] | | | | |
2016-002716-41: A STUDY TO EVALUATE LONG TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCE |
|
|
| Not yet recruiting | 3 | 10 | Europe | Solution for injection, RoActemra 162 mg solution for injection in pre-filled syringe | ROCHE SAS, ROCHE SAS | Giant cell arteritis (GCA), An inflammatory disease of the blood vessels that typically occurs in individuals over 50 years of age. It can cause fever, headache, jaw or mouth pain and can lead to irreversible vision loss, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-001213-17: Efficacy and Safety of bulevirtide in patients with Chronic Hepatitis Delta |
|
|
| Not yet recruiting | 3 | 150 | Europe | bulevirtide, [bulevirtide], Lyophilisate for solution for injection | Gilead Sciences, Inc., Gilead Sciences, Inc, MYR GmbH, MYR GmbH, Gilead Sciences, Inc. | Chronic Hepatitis Delta, Chronic Hepatitis Delta, Diseases [C] - Virus Diseases [C02] | | | | |
| Terminated | 3 | 219 | Europe, US, RoW | OSE2101, TEDOPI, EP-2101, EP2101, IDM-2101, Docetaxel, Taxotere, Pemetrexed, Alimta | OSE Immunotherapeutics, OSE Immunotherapeutics, OSE Pharma | Non Small Cell Lung Cancer | 01/21 | 01/21 | | |
NCT03511625: The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis |
|
|
| Active, not recruiting | 3 | 6 | US | Acthar Injectable Product, repository corticotropin injection, H.P. Acthar Gel, Depo medrol, methylprednisolone acetate injectable suspension | Attune Health Research, Inc., Mallinckrodt | Rheumatoid Arthritis | 02/20 | 12/24 | | |
2019-003151-11: Stelara for Chronic AntibioTic refractory inflammation of the pouch: A Belgian multicenter study |
|
|
| Not yet recruiting | 3 | 20 | Europe | Stelara, Injection, ustekinumab (Stelara) | UZ Leuven, Janssen | Chronic antibiotic refractory and relapsing pouchitis, Chronic antibiotic refractory and relapsing inflammation of the pouch, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT03903796: Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection |
|
|
| Active, not recruiting | 3 | 963 | RoW | HS-10234, TDF | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic HBV Infection | 05/20 | 09/23 | | |
2019-004961-42: Strategy study in patients with peripheral spondyloarthritis, in which it is investigated whether induction of remission can be achieved more quickly with early treatment with a TNF-alpha blocker, compared to standard treatment, and in which also factors (blood, joint biopsy) that predict these outcome are investigated. Strategie-studie bij patiënten met perifere spondyloartritis, waarbij nagegaan wordt of inductie van remissie sneller bereikt kan worden met vroegtijdige behandeling met een TNF-alfa blokker, in vergelijking met de standaardbehandeling, en waarbij tevens onderzoek gebeurt naar factoren (bloed, gewrichtsbiopsie) die deze uitkomst zouden kunnen voorspellen. |
|
|
| Not yet recruiting | 3 | 112 | Europe | Capsule, Solution for injection in pre-filled injector, Solution for injection in pre-filled syringe, Ledertrexate, Simponi | Ghent University Hospital, VIB vzw, MSD Belgium | peripheral spondyloarthritis Perifere spondyloartritis, rheumatic inflammatory disease against the joints and tendons outside the vertebral column reumatische ontstekingsziekte tegenover de gewrichten en pezen buiten de wervelzuil, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Active, not recruiting | 3 | 27 | US | Tenofovir Alafenamide, TAF | Thomas Jefferson University, Gilead Sciences | Hepatitis B | 08/20 | 09/20 | | |
2016-003078-41: Influence of treatment with Phlogenzym® on recovery after total hip replacement as a model. |
|
|
| Not yet recruiting | 3 | 40 | RoW | Phlogenzym, Coated tablet, Phlogenzym | MUCOS Pharma CZ s.r.o., Mucos Pharma CZ s.r.o. | Total hip replacement, Total hip replacement, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-003715-22: Efficacy and Safety Evaluation for the Treatment of asthma and allergic rhinitis/rhinoconjunctivitis Evaluación de la eficacia y seguridad del tratamiento del asma y de la rinitis/rinoconjuntivitis alergica a gramíneas y ácaros de polvo. |
|
|
| Not yet recruiting | 3 | 140 | Europe | MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000), Suspension for injection | Inmunotek, S.L., Inmunotek, S.L. | Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen. Asma de leve a moderada y rinitis/rinoconjuntivitis alérgica (intermitente o persistente) debida a hipersensibilidad a ácaros de polvo (Dermatophagoides pteronyssinus y/o D. farinae) y polen de gramíneas., Grass and house dust mite allergy (asthma and rhinitis/rhinoconjunctivitis) Alergia frente a gramíneas y ácaros de polvo (asma y rinitis/rinoconjuntivitis), Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002811-25: Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis sensitized to grass and olive pollen Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a gramíneas y olivo |
|
|
| Not yet recruiting | 3 | 180 | Europe | MG01-T517 (10.000-10.000), MG01-T517-(30.000-10.000), Solution for injection | Inmunotek, S.L., INMUNOTEK, S.L. | Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and olive pollen Rinitis alérgica / rinoconjuntivitis con o sin asma leve a moderada por sensibilización a pólen de gramineas y olivo, Grasses and olive tree allergy Alergia frente a Gramíneas y Olivo, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002865-37: Efficacy and Safety Evaluation for the Treatment of Allergy Against Cupressaceae and grasses. Evaluación de la eficacia y seguridad del tratamiento de la alergia a gramíneas y cupresáceas |
|
|
| Not yet recruiting | 3 | 180 | Europe | MG01-T521 (10.000-10.000), MG01-T521 (30.000-10.000), Solution for injection | Inmunotek, S.L., INMUNOTEK, S.L. | Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and cupressaceae pollen Rinitis alérgica / rinoconjuntivitis con o sin asma leve a moderada por sensibilización a pólen de gramineas y cupresáceas, Grasses and cupressacease allergy Alergia frente a Gramíneas y cupresáceas, Diseases [C] - Immune System Diseases [C20] | | | | |
MYR 301, NCT03852719: Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) |
|
|
| Active, not recruiting | 3 | 150 | Europe, US, RoW | Bulevirtide, Myrcludex B, Hepcludex® | Gilead Sciences | Chronic Hepatitis Delta | 11/20 | 07/24 | | |
2020-000195-38: Efficacy and safety of benralizumab for prevention of nasal polyps recurrence following endoscopic sino-nasal surgery |
|
|
| Not yet recruiting | 3 | 200 | Europe | Benralizumab, MEDI-563, Solution for injection in pre-filled syringe | AstraZeneca AB, AstraZeneca AB | Nasal polyposis, Nasal polyposis (NP) is a chronic inflammatory disease of the nasal mucosa characterized by the presence of polyps in the upper nasal cavity., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-001314-37: clinical study to show equal clinical efficacy of two dosing regimen of budesonid orodispersible tablets (twice daily vs. once daily) for treatment of inflammation of the esophagus |
|
|
| Not yet recruiting | 3 | 242 | Europe | Budesonide 2 mg orodispersible tablets (BUL 2 mg), Budesonide 1 mg orodispersible tablets (BUL 1 mg), Orodispersible tablet, Jorveza | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | eosinophilic esophagitis Eosinophile Ösophagitis, allergy-like, chronic inflammation of the esophagus allergieartige, chronische Entzündung der Speiseröhre, Diseases [C] - Digestive System Diseases [C06] | | | | |
2017-003516-39: A phase III clinical study in adult and adolescent patients with eosinophilic inflammation of the gullet to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining remission Klinische Studie der Phase III mit erwachsenen und jugendlichen Patienten mit eosinophiler Entzündung der Speiseröhre zum Nachweis der Überlegenheit einer 48-wöchigen Behandlung in Episoden und/oder fortlaufend mit Budesonid Schmelztabletten im Vergleich zu Plazebo zur Aufrechterhaltung einer Remission. |
|
|
| Ongoing | 3 | 110 | Europe | Budesonide 1 mg orodispersible tablets, Budesonide 0.5 mg orodispersible tablets, BUL 1 mg, BUL 0.5 mg, Orodispersible tablet, Jorveza 1 mg orodispersible tablets, Jorveza 0.5 mg orodispersible tablets | Dr. Falk Pharma GmbH, DR. FALK PHARMA GMBH, Dr. Falk Pharma GmbH, DR. FALK PHARMA GmbH | Maintenance of remission in eosinophilic esophagitis Remissionserhalt der eosinophilen Ösophagitis, Chronic allergic/immune-mediated inflammatory disease of the gullet in its remission phase Chronisch allergische/immun-vermittelte entzündliche Erkrankung der Speiseröhre in ihrer Remissionsphase, Diseases [C] - Digestive System Diseases [C06] | | | | |
2020-005624-10: The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces any hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation |
|
|
| Ongoing | 3 | 1000 | Europe | Clexane (enoxaparin sodium), Solution for injection in pre-filled syringe, Clexane (enoxaparin sodium) | University Hospital Zurich, Clinic of Angiology, Universitaetsspital Zuerich, Schweizerischer Nationalfunds (SNF) | Patients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation., COVID-19 Infection, Diseases [C] - Virus Diseases [C02] | | | | |
2020-004853-59: ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation ZEUS- klinikinis tyrimas kuriuo stebima kaip veikia Ziltevikimabas lyginant su placebo žmonėms su terosklerozinė širdies ir kraujagyslių liga, lėtinė inkstų liga bei sisteminiu uždegimu |
|
|
| Ongoing | 3 | 6200 | Europe, RoW | Ziltivekimab B 15 mg/mL DV3430-C1, [.], Solution for injection | Novo Nordisk A/S, NOVO NORDISK. S.P.A., Novo Nordisk A/S | Atherosclerotic cardiovascular diseaseChronic kidney disease Systemic inflammation aterosklerozinė širdies ir kraujagyslių liga,lėtinė inkstų liga sisteminis uždegimas, Cardiovascular diseaseChronic kidney diseaseInflammation aterosklerozinė širdies ir kraujagyslių liga,lėtinė inkstų liga sisteminis uždegimas, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-002579-33: To Evaluate the Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis |
|
|
| Not yet recruiting | 3 | 1000 | Europe | Vonoprazan 10 mg, Agopton, Vonoprazan 20 mg, Tablet, Capsule, Agopton (Lansoprazole) 15 mg, Agopton (Lansoprazole) 30 mg | Phathom Pharmaceuticals, Inc., Phathom Pharmaceuticals, Inc. | Erosive Esophagitis, An inflammation of the cell layer that lines the inside of esophagus. A disease that causes heartburn, a burning sensation in the throat and difficulty and pain when swallowing., Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
2020-004529-22: Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 3 | 360 | Europe, RoW | Anifrolumab, MEDI-546, Solution for injection in pre-filled syringe, SAPHNELO | AstraZeneca, AstraZeneca | Moderate-to-severe Systemic Lupus Erythematosus (SLE), Systemic Lupus Erythematosus is a disease in which the body's own immune system attacks its own cells and tissues, leading to inflammation and damage., Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000345-41: Extension of the RESCUE study to follow up on long term safety and efficacy of patients with Crohn's disease that received a dose escalation after the loss of response to ustekinumab Extension de l'étude RESCUE pour suivre la sécurité et l'efficacité à long terme des patients atteints de la maladie de Crohn qui ont reçu une augmentation de dose après la perte de réponse à l'ustekinumab. Uitbreiding van de RESCUE-studie met het oog op de follow-up van de veiligheid en doeltreffendheid op lange termijn van patiënten met de ziekte van Crohn die een dosisescalatie hebben gekregen na het verlies van respons op ustekinumab |
|
|
| Not yet recruiting | 3 | 108 | Europe | Solution for injection in pre-filled syringe, Stelara 90 mg solution for injection n pre-filled syringue | Belgian IBD research and development (BIRD vzw), Janssen Pharmaceutica NV | Crohn's disease ziekte van Crohn La maladie de Crohn, Chronic inflammatory bowel disease Chronische inflammatoire darmziekte La maladie inflammatoire chronique de l'intestin, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Not yet recruiting | 3 | 350 | Europe | Beltavac® with polymerized extract from Dermatophagoides, Suspension for injection | Probelte Pharma S.L.U., NA | Allergic rhinitis/ rhinoconjuntivitis associated or not with asthma rinitis/rinoconjuntivitis alérgica asociada o no con asma, House dust mite allergy Alergia a los ácaros del polvo, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-004300-34: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS |
|
|
| Not yet recruiting | 3 | 225 | Europe | Lebrikizumab, DRM06, Solution for injection in pre-filled syringe | Dermira, Inc., Dermira, Inc. | Atopic dermatitis, Atopic dermatitis (AD) or eczema is a common inflammatory skin disease characterized by dry skin, red and crusting rash and intense pruritus (itch) that may affect people of all ages., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-002765-34: A Study Comparing MabionCD20 (new Rituximab biosimilar) with MabThera (reference Rituximab from EU) and Rituxan (reference Rituximab from US) in Patients with Rheumatoid Arthritis |
|
|
| Not yet recruiting | 3 | 280 | Europe | MabionCD20, Concentrate for solution for infusion, MabThera, Rituxan | Mabion S.A., Mabion S.A. | Moderate-to-severe rheumatoid arthritis, Rheumatoid Arthritis is a disease which causes joint inflammation and pain. The study is done in patients with rheumatoid arthritis of moderate to severe activity., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-001448-90: A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis |
|
|
| Not yet recruiting | 3 | 45 | Europe | ANB019, Solution for injection, Solution for infusion | AnaptysBio Inc., AnaptysBio Inc. | Subjects with generalized pustular psoriasis, GPP is a severe,debilitating,and life-threatening systemic inflammatory disease.Skin lesions manifest with widespread sterile pustules on erythematous skin covering almost the entire body., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento |
|
|
| Not yet recruiting | 3 | 100 | Europe | satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng | F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,è un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10] | | | | |
2021-004003-41: A study to evaluate the safety and immune response to an unadjuvanted RSV maternal vaccine in healthy non-pregnant females from 9 to 49 years of age. Estudio para evaluar la seguridad y la respuesta inmune a la vacuna no potenciada para inmunización materna frente al Virus Respiratorio Sincitial (VRS) en mujeres sanas no embarazadas de 9 a 49 años de edad. |
|
|
| Not yet recruiting | 3 | 252 | Europe | RSVPreF3, Boostrix, GSK3888550A, dTpa, Powder and solvent for solution for injection, Suspension for injection, Boostrix | GlaxoSmithKline, S.A., GlaxoSmithKline Biologicals | Healthy volunteers (prevention of RSV-associated lower respiratory tract illnesses (LRTIs)) Voluntarios sanos (prevención de las enfermedades del tracto respiratorio inferior (LRTI) asociadas al VRS), RSV is a very common virus that leads to mild, cold-like symptoms in adults and children. RSV can cause more serious disease in infants, such as inflammation of the lungs. El VSR es un virus muy común que provoca síntomas leves similares a los de un resfriado en adultos y niños. El VSR puede causar enfermedades más graves en los bebés, como inflamación de los pulmones., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT03547908 / 2018-000926-79: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults |
|
|
| Completed | 3 | 244 | Europe, Japan, US, RoW | B/F/TAF, Biktarvy®, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Truvada®, Placebo to match B/F/TAF | Gilead Sciences | HIV-1/HBV Co-Infection | 02/22 | 03/24 | | |
2019-003407-35: A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus Estudio para evaluar la eficacia y la seguridad del dapirolizumab pegol en participantes en el estudio con lupus eritematoso sistémico de moderado a grave |
|
|
| Ongoing | 3 | 450 | Europe | Dapirolizumab pegol, CDP7657, Powder for solution for infusion | UCB Biopharma SRL, UCB Biopharma SRL | Systemic lupus erythematosus (SLE) Lupus eritematoso sistémico (SLE), Systemic lupus erythematosus is a chronic autoimmune inflammatory disease which can present with a persistent active disease coursebut has more often a relapsing-remitting disease course El lupus eritematoso sistémico es una enfermedad inflamatoria crónica de carácter autoinmunitario que, aunque puede presentar un curso crónico, por lo común presenta un curso recidivante-remitente., Body processes [G] - Immune system processes [G12] | | | | |
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder |
|
|
| Not yet recruiting | 3 | 8 | Europe | Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-005830-14: Study of safety, efficacy and tolerability of ianalumab versus placebo, in combination with SOC therapy, in participants with active lupus nephritis Randomizált, kettős vak, párhuzamos csoportos, placebo kontrollos,multicentrikus, III. fázisú vizsgálat a hagyományos kezelés mellett alkalmazott ianalumab hatásosságának, biztonságosságának és tolerálhatóságának értékelésére aktív lupus nephritisben szenvedő résztvevők körében (SIRIUS-LN) |
|
|
| Ongoing | 3 | 420 | Europe, RoW | ianalumab, VAY736, Solution for injection in pre-filled syringe | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Lupus nephritis, Inflammation of the kidneys that is a severe complication of systemic lupus, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-006165-11: GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s Disease GRAVITI - Estudio de fase 3 para evaluar la eficacia y la seguridad del tratamiento de inducción con guselkumab subcutáneo en participantes con enfermedad de Crohn activa de grado moderado o severo |
|
|
| Ongoing | 3 | 318 | Europe, RoW | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development | Moderately to Severely Active Crohn's Disease Enfermedad de Crohn activa de grado moderado o severo, Inflammatory bowel disease (IBD) Enfermedad inflamatoria intestinal, Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 3 | 370 | Europe, Canada, Japan, US, RoW | Monalizumab, IPH2201, Cetuximab, Erbitux, Placebo | AstraZeneca, Innate Pharma | Squamous Cell Carcinoma of the Head and Neck | 05/22 | 06/24 | | |
|
NCT05106335: A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC |
|
|
| Terminated | 3 | 1 | RoW | camrelizumab + famitinib, famitinib, docetaxel | Jiangsu HengRui Medicine Co., Ltd. | Advanced NSCLC | 05/22 | 05/22 | | |
2021-003702-42: A Phase 3 Placebo-controlled Efficacy and Safety Study with Ritlecitinib (PF-06651600) in Adults with Moderately to Severely Active UC Estudio en fase III controlado con placebo de la eficacia y la seguridad de ritlecitinib (PF-06651600) en adultos con CU activa de moderada a grave. |
|
|
| Ongoing | 3 | 432 | Europe | Ritlecitinib, PF-06651600, Capsule | Pfizer Inc., Pfizer Inc. | Moderate to Severe Ulcerative Colitis (UC) Colitis ulcerosa de moderada a grave, Ulcerative colitis is a chronic inflammatory condition of the gastrointestinal tract characterised by continuous inflammation that is localised to the colon La colitis ulcerosa es una afección inflamatoria crónica del tracto gastrointestinal caracterizada por una inflamación continua que se localiza en el colon., Diseases [C] - Immune System Diseases [C20] | | | | |
2021-002252-36: A prospective, randomized, double-blind placebo-controlled multicentre study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis. |
|
|
| Not yet recruiting | 3 | 360 | Europe | T502 10 000 mTU/mL, Suspension for injection | Inmunotek S.L., Inmunotek S.L. | Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis. Behandlung der durch Birkenpollen ausgelösten allergischen Rhinitisoder Konjunktivitis., Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis. Behandlung der durch Birkenpollen ausgelösten allergischen Rhinitisoder Konjunktivitis., Diseases [C] - Ear, nose and throat diseases [C09] | | | | |
2019-004301-28: AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS |
|
|
| Not yet recruiting | 3 | 200 | Europe | Lebrikizumab, DRM06, Solution for injection in pre-filled syringe | Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company | Atopic dermatitis, Atopic dermatitis (AD) or eczema is a common inflammatory skin disease characterized by dry skin, red and crusting rash and intense pruritus (itch) that may affect people of all ages., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-000491-10: FUZION - Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease ÚÄinnost a bezpeÄnost pÅ™Ãpravku guselkumab u pacientů s fistulujÃcà formou perianálnà Crohnovy nemoci |
|
|
| Ongoing | 3 | 280 | RoW, Europe | Guselkumab, CNTO1959, Solution for infusion, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development | Fistulizing perianal Crohn's Disease, Inflammatory bowel disease (IBD), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04810962: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study |
|
|
| Completed | 3 | 370 | US | APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05% | Formosa Pharmaceuticals, Inc. | Ocular Inflammation and Pain After Cataract Surgery | 07/22 | 07/22 | | |
2021-005772-19: An extension clinical trial of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis Un estudio de extensión de secukinumab subcutáneo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo en pacientes con nefritis lúpica activa. |
|
|
| Ongoing | 3 | 310 | Europe, RoW | Solution for injection in pre-filled syringe, Cosentyx | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Lupus Nephritis Nefritis lúpica, Lupus Nephritis is an inflammation of kidneys caused by systemic lupuserythematosus, an autoimmune disease (body's immune system targetsits own body tissues) that can affect any part of the body. Nefritis lúpica:inflamación de los riñones causada por lupus eritematoso sistémico,enfermedad autoinmune (el sistema inmune ataca a los tejidos propios) que puede afectar a cualquier parte del cuerpo, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 3 | 408 | NA | Galactomannan, PLACEBO | Bioxytran Inc., ALKE RESEARCH PRIVATE LIMITED, Research Consultancy | COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection, Cytokine Release Syndrome | 07/22 | 09/22 | | |
NCT04539548: A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract |
|
|
| Completed | 3 | 65 | US | Dextenza Ophthalmic Insert, DEXTENZA, Prednisolone acetate ophthalmic suspension USP 1% | Ocular Therapeutix, Inc. | Cataract | 12/23 | 12/23 | | |
2019-001517-16: Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen |
|
|
| Not yet recruiting | 3 | 1342 | Europe, RoW | PQ Grass, Suspension for injection | Allergy Therapeutics (UK) Ltd., Allergy Therapeutics (UK) Ltd. | Seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure, grass pollen allergy, Body processes [G] - Immune system processes [G12] | | | | |
2022-000624-37: Clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age. Ensayo clínico para evaluar la seguridad y eficacia de clobetasol propionato 0,05% nanoemulsión oftálmica en comparación con acetato de prednisolona 1% en el tratamiento de la inflamación después de la cirugía de cataratas en población pediátrica de 0 a 3 años. |
|
|
| Not yet recruiting | 3 | 60 | Europe | Clobetasol propionate ophthalmic nanoemulsion, 0.05%, Clobetasol propionate, Ear/eye drops, solution, Ear/eye drops, suspension, Pred Forte 10 mg/ml colirio en suspensión | Laboratorios Salvat, S.A., Laboratorios Salvat, S.A. | Inflammation and pain associated with ocular surgery. Inflamación y dolor después de la cirugía de cataratas., Inflammation and pain associated with ocular surgery. Inflamación y dolor después de la cirugía de cataratas., Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
| Active, not recruiting | 3 | 198 | RoW | Olokizumab, Standard therapy | R-Pharm, Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС | COVID-19 | 10/22 | 04/23 | | |
NCT05482295: Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) |
|
|
| Not yet recruiting | 3 | 540 | NA | Hepatitis B vaccine lot 1, Hepatitis B vaccine lot 2, Hepatitis B vaccine lot 3, Hepatitis B vaccine (registered) | PT Bio Farma, RS Umum Pusat Sanglah, Denpasar | Vaccine Reaction, Vaccine Adverse Reaction | 07/24 | 08/24 | | |
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente. |
|
|
| Ongoing | 3 | 212 | Europe, RoW | Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules | Janssen-Cilag International NV, Janssen Research & Development, LLC | Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-000257-83: A large global research study for an investigational drug called atacicept is being tested for the treatment of active lupus nephritis in a randomized manner, and is a placebo-controlled, double-blind study. Placebo-controlled provides a way to measure the actual effect of the investigational drug (atacicept). Double-blind means that the patient and the study doctor will not know if the patient is getting atacicept or placebo. |
|
|
| Not yet recruiting | 3 | 290 | Europe | Atacicept, VT-001, Solution for injection in pre-filled syringe | Vera Therapeutics, Inc., Vera Therapeutics, Inc. | patients with lupus nephritis sujetos con nefritis lúpica, Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease; a disorder in which the body's immune system attacks the body's own cells and organs., Body processes [G] - Immune system processes [G12] | | | | |
| Completed | 3 | 20 | Europe | Ustekinumab, Stelara | Universitaire Ziekenhuizen KU Leuven, Janssen, LP | Pouchitis | 12/22 | 05/23 | | |
NCT05482282: Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) |
|
|
| Not yet recruiting | 3 | 220 | RoW | Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma), Pentabio | PT Bio Farma, Hasan Sadikin General Hospital | Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction, Haemophilus Influenzae Type B Vaccine Adverse Reaction, Hepatitis B Vaccine Adverse Reaction | 04/25 | 07/25 | | |
2021-005139-22: Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Estudio Fase III con bepirovirsen en pacientes con Hepatitis B crónica en tratamiento con análogos de nucleós(t)idos (B-Well 1). |
|
|
| Ongoing | 3 | 534 | Europe | Bepirovirsen, Bepirovirsen, Solution for injection | GlaxoSmithKline Research & Development Limited, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B infection Infección crónica por hepatitis B, Chronic Hepatitis B infection Infección crónica por hepatitis B, Diseases [C] - Virus Diseases [C02] | | | | |
2022-002268-53: Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Estudio Fase III con bepirovirsen en pacientes con Hepatitis B crónica en tratamiento con análogos de nucleós(t)idos (B-Well 2). |
|
|
| Ongoing | 3 | 534 | Europe | Bepirovirsen, Bepirovirsen, Solution for injection | GlaxoSmithKline Research & Development Limited, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B infection Infección crónica por hepatitis B, Chronic Hepatitis B infection Infección crónica por hepatitis B, Diseases [C] - Virus Diseases [C02] | | | | |
2022-002691-36: Phase 3 study to evaluate two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1) Estudio de fase III en el que se evalúan dos pautas posológicas de ianalumab en combinación con el tratamiento de referencia en pacientes con lupus eritematoso sistémico (SIRIUS-SLE 1) |
|
|
| Ongoing | 3 | 406 | Europe | ianalumab, VAY736, Solution for injection in pre-filled syringe | Novartis Farmacéutica, S.A., Novartis Pharma AG | Systemic Lupus Erythematosus Lupus eritematoso sistémico, An inflammatory disease caused when the immune system attacks its own tissues. Una enfermedad inflamatoria causada cuando el sistema inmune ataca sus propios tejidos., Diseases [C] - Immune System Diseases [C20] | | | | |
CONTACT-03, NCT04338269 / 2020-000502-29: A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment |
|
|
| Active, not recruiting | 3 | 522 | Europe, Canada, Japan, US, RoW | Atezolizumab, Tecentriq, Cabozantinib, Cabometyx | Hoffmann-La Roche, Exelixis, Chugai | Carcinoma, Renal Cell | 01/23 | 06/24 | | |
|
|
|
NCT04981717 / 2021-002089-42: A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat |
|
|
| Terminated | 3 | 446 | Europe, Canada, US | REGN1908-1909, Matching Placebo | Regeneron Pharmaceuticals | Allergic Rhinitis Due to Cat Allergy | 01/23 | 04/23 | | |
2018-002629-51: A Clinical Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Chronic Inflammatory Bowel Disease That Affects the Lining of the Digestive Tract |
|
|
| Not yet recruiting | 3 | 200 | Europe, RoW | Ustekinumab, CNTO1275, Solution for injection in pre-filled syringe, Concentrate for solution for infusion, STELARA® | Janssen-Cilag International NV, Janssen-Cilag International N.V., JANSSEN CILAG INTERNATIONAL NV, Janssen Pharmaceutica NV, Janssen Pharmaceutica NV Belgium, Janssen-Cilag SpA | Crohn’s Disease, A chronic inflammatory bowel disease that affects the lining of the digestive tract, Diseases [C] - Immune System Diseases [C20] | | | | |
2022-000365-41: A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis Estudio de fase 3 para evaluar la eficacia y la seguridad del tratamiento de inducción con guselkumab subcutáneo en participantes con colitis ulcerosa activa de grado moderado a severo |
|
|
| Ongoing | 3 | 399 | Europe, RoW | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development | Moderately to Severely Active Ulcerative Colitis Colitis ulcerosa activa de grado moderado a severo, Inflammatory bowel disease (IBD) Enfermedad inflamatoria intestinal (EII), Diseases [C] - Immune System Diseases [C20] | | | | |
2022-002977-27: This study will evaluate and confirm that a new formulation of Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals is therapeutically equivalent to the marketed formulation Advair DISKUS® 100/50 mcg inhalation powder/GSK in patients with asthma Aυτή η μελέτη θα αξιολογήσει και τεκμηριώσει ότι ένα νέο σκευάσμα Προπιονικής Φλουτικαζόνης 100mcg και Σαλμετερόλης 50mcg/Respirent Pharmaceuticals κόνις για εισπνοή είναι θεραπευτικά ισοδύναμο του εγκεκριμένου σκευάσματος ADVAIR DISKUS® 100/50mcg κόνις για εισπνοή/GSK σε ασθενείς με άσθμα |
|
|
| Ongoing | 3 | 451 | Europe | Fluticasone propionate 100μg/salmeterol 50μg (as xinafoate) inhalation powder/Respirent, Inhalation powder, pre-dispensed, ADVAIR DISKUS® | Respirent Pharmaceuticals Co. Ltd, Respirent Pharmaceuticals Co. Ltd | Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation Το άσθμα είναι μια ετερογενής ασθένεια, που συνήθως χαρακτηρίζεται από χρόνια φλεγμονή των αεραγωγών. Ορίζεται από ιστορικό αναπνευστικών συμπτωμάτων όπως συριγμός, δυσκολία στην αναπνοή, σφίξιμο στο στήθος και βήχα που μεταβάλλονται στο χρόνο αλλά και σε ένταση, μαζί με μια μεταβλητή απόφραξη των αεραγωγών., Asthma is a chronic inflammatory disease of the airways that is complex and characterized by symptoms as airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation. Το άσθμα είναι μια χρόνια φλεγμονώδης νόσος των αεραγωγών που είναι σύνθετη και χαρακτηρίζεται από συμπτώματα οπως απόφραξη της ροής του αέρα, βρογχική υπεραντιδραστικότητα και υποκείμενη φλεγμονή, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2022-003024-41: Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Psoriatic Arthritis Estudio de fase 3 de extensión a largo plazo y abierto de apremilast en niños con úlceras bucales asociadas a la enfermedad de Behçet o con artritis psoriásica juvenil |
|
|
| Ongoing | 3 | 48 | Europe | Apremilast 20 mg, Apremilast 30 mg, Apremilast, AMG 407, Film-coated tablet, Oral suspension, Otezla | Amgen Inc, Amgen Inc. | Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis Sujetos con enfermedad de Behçet o artritis psoriásica juvenil activa, Behçet Disease: inflammation in blood vessels throughout the body, manifests as mouth or genital ulcers with eye & skin lesionsJPA:Joint inflammation with psoriatic disorder affecting pediatric pts EB:inflamación en los vasos sanguineos, se manifiestan ulceras bucales/genitales y lesiones en los ojos/pielAIJ:inflamación de las articulaciones con desorden psoriasico que afecta a pts pediatricos, Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 3 | 939 | Europe, Canada, Japan, US, RoW | Dupilumab SAR231893, Dupixent, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo | Sanofi, Regeneron Pharmaceuticals | Chronic Obstructive Pulmonary Disease | 02/23 | 05/23 | | |
|
|
|
|
|
2019-003334-16: Novel budenosid suppository in addition to basic therapy with oral mesalazine compared to basic therapy alone for treatment of ulcerative colitis |
|
|
| Not yet recruiting | 3 | 360 | Europe, RoW | Budenofalk® suppositories, Salofalk 3g gastro-resistant prolonged-release granules, Suppository, Gastro-resistant granules, Salofalk 3g gastro-resistant prolonged-release granules | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | acute ulcerative colitis, acute ulcerative colitis - inflammation and ulcers of the colon and rectum, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT02600117: Use of TDF in Patients With Inactive Chronic Hepatitis B Infection |
|
|
| Completed | 3 | 50 | Canada | Tenofovir disoproxil fumarate, Viread | University Health Network, Toronto, Gilead Sciences | Hepatitis B, Chronic | 02/23 | 02/23 | | |
NCT05147233: OCS-01: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
|
|
| Recruiting | 3 | 240 | US | Dexamethasone, OCS-01, Vehicle Placebo, Placebo | Oculis | Disorders of the Eye Following Cataract Surgery | 03/23 | 06/23 | | |
| Completed | 3 | 210 | RoW | AI201901, Azelastine Hydrochloride, Allergodil | Abdi Ibrahim Ilac San. ve Tic A.S., Istanbul Umraniye Training and Research Hospital, Diskapi Yildirim Beyazit Education and Research Hospital, Antalya Training and Research Hospital, Dokuz Eylul University, Ankara City Hospital Bilkent, Kahramanmaras Sutcu Imam University, Uludag University, Karadeniz Technical University, Kartal Dr. Lütfi Kirdar City Hospital | Allergic Rhinitis Due to Allergens | 03/23 | 05/23 | | |
2022-002690-29: Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) |
|
|
| Not yet recruiting | 3 | 280 | Europe | ianalumab, VAY736, Solution for injection in pre-filled syringe | Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Pharma AG | Systemic Lupus Erythematosus, An inflammatory disease caused when the immune system attacks its own tissues., Diseases [C] - Immune System Diseases [C20] | | | | |
2022-003384-24: A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer’s disease |
|
|
| Ongoing | 3 | 24 | Europe | Solution for injection, Ozempic® | Novo Nordisk A/S, Novo Nordisk A/S | Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type, Early Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-002677-19: Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLF |
|
|
| Not yet recruiting | 3 | 250 | Europe | Albutein 5%, [B05AA01], Solution for infusion, Human Albumin Grifols 50g/l | Instituto Grifols S.A., INSTITUTO GRIFOLS, S.A., Instituto Grifols S.A. | Group 1 and 2:Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or duringhospitalization Group 3: Subject with cirrhosis hospitalized for Acute decompensation of cirrhosis (ascites, hepatic encephalopathy [HE], gastrointestinal hemorrhage, and/or bacterial infections), Group 1 and 2: Subjects with cirrhosis and diagnosed Acute-on-Chronic Liver FailureGroup 3: Subjects with cirrhosis without diagnosed Acute-on-Chronic Liver Failure, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 3 | 1460 | Europe, Canada, US, RoW | Sublingual allergy immunotherapy tablet, Acarizax, Odactra, Placebo, Placebo sublingual tablet | ALK-Abelló A/S | Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite | 04/23 | 04/23 | | |
2021-003014-39: Efficacy and Safety Evaluation for the Treatment of house dust mite induced allergic asthma and rhinitis/rhinoconjunctivitis Evaluación de la eficacia y seguridad del tratamiento del asma y de la rinitis/rinoconjuntivitis alergica a ácaros de polvo doméstico. |
|
|
| Not yet recruiting | 3 | 400 | Europe | MM09 allergoid-mannan conjugates SC (3.000), MM09 allergoid-mannan conjugates SL (3.000), MM09 allergoid-mannan conjugates SL (9.000), Solution for injection, Sublingual spray, solution | Inmunotek, S.L., Inmunotek, S.L. | Etiological treatment of mild to moderate controlled intermittent or persistent allergic asthma and intermittent or persistent allergic rhinitis / rhinoconjunctivitis Tratamiento etiológico de asma alérgica intermitente o persistente controlada de leve a moderada y rinitis/rinoconjuntivitis alérgica intermitente o persistente, House dust mite induced allergy (asthma and rhinitis/rhinoconjunctivitis) Alergia frente a ácaros de polvo doméstico (asma y rinitis/rinoconjuntivitis), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-005382-40: A new medication (capsules) for treatment of Rosacea (a type of skin inflammation) |
|
|
| Not yet recruiting | 3 | 320 | Europe | DFD-29, Capsule | Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Journey Medical Corporation | Rosacea, Rosacea is a common skin condition that causes blushing or flushing and visible blood vessels in the face. It may also produce small, pus-filled bumps., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05590598: Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis. |
|
|
| Completed | 3 | 472 | RoW | Azelastine + Mometazone, nasal spray, Momat Rhino Advance | Sandoz | Seasonal Allergic Rhinitis | 06/23 | 06/23 | | |
2022-001682-12: A study to assess the efficacy of a cardiac drug and a anti-inflammatory drug in patients with post-acute inflammatory heart disease due to COVID-19 |
|
|
| Not yet recruiting | 3 | 280 | Europe | Losartan-Kalium, Prednisolon 10 mg, Prednisolon, Capsule, hard, Losartan-Kalium TAD® 12,5 mg Filmtabletten, Losartan-Kalium TAD® 25 mg Filmtabletten, Prednisolon 10 mg JENAPHARM®, Prednisolon 5 mg JENAPHARM® | Goethe University Frankfurt, Bayer AG | Inflammatory cardiovascular involvement due to COVID-19, defined by Cardiovascular magnetic resonance imaging, COVID-19 disease with cardiovascular inflammatory involvement, Diseases [C] - Virus Diseases [C02] | | | | |
2021-004050-31: Efficacy and safety of the combination Mometasone furoate + Azelastine hydrochloride nasal spray in the treatment of seasonal allergic rhinitis |
|
|
| Not yet recruiting | 3 | 700 | Europe, RoW | Mometasone + Azelastine (50 + 140 mcg per actuation), Mometasone furoate nasal spray (50 mcg per actuation), Azelastine hydrochloride nasal spray (140 mcg per actuation), Test, Comparator 1, Comparator 2, Nasal spray | Lek Pharmaceuticals d.d., Lek Pharmaceuticals d.d. | Seasonal allergic rhinitis, Seasonal allergic rhinitis, Diseases [C] - Ear, nose and throat diseases [C09] | | | | |
NCT05311475: Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis |
|
|
| Completed | 3 | 669 | Europe, RoW | Mometasone, Azelastine, Placebo | Sandoz | Seasonal Allergic Rhinitis | 06/23 | 06/23 | | |
